A Phase II, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Patients With Hydroxyurea-Resistant/Intolerant Polycythemia Vera
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Idasanutlin (Primary)
- Indications Polycythaemia vera
- Focus Therapeutic Use
- Sponsors Roche
- 16 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 24 Sep 2019 Planned number of patients changed from 20 to 100.
- 24 Sep 2019 Planned End Date changed from 30 Mar 2021 to 20 Oct 2022.